EMPA-VISION: A Randomised, Double-blind, Placebo-controlled, Mechanistic Cardiac Magnetic Resonance Study to Investigate the Effects of Empagliflozin Treatment on Cardiac Physiology and Metabolism in Patients With Heart Failure
Phase of Trial: Phase III
Latest Information Update: 03 Sep 2018
At a glance
- Drugs Empagliflozin (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms EMPA-VISION
- Sponsors Boehringer Ingelheim
- 26 Jun 2018 Planned End Date changed from 6 Mar 2019 to 31 Oct 2019.
- 26 Jun 2018 Planned primary completion date changed from 27 Feb 2019 to 24 Oct 2019.
- 05 Mar 2018 Status changed from not yet recruiting to recruiting.